Drug Discovery

Celgene, BeiGene to advance PD-1 inhibitor for solid tumor cancers

Celgene has agreed to develop and commercialize BeiGene’s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317 for the treatment of solid tumor cancers.

Alexion signs funding deal with NICE and NHS England for Strensiq

Alexion Pharmaceuticals has signed a national funding agreement with the National Institute for Health and Care Excellence (NICE) and the National Health Service (NHS) England based on a Managed Access Agreement (MAA), which provides access to Strensiq (asfotase alfa) for patients in England with pediatric-onset hypophosphatasia (HPP), regardless of their current age.

CytomX advances CD71-targeting probody drug conjugate into GLP toxicology studies

CytomX Therapeutics has advanced CX-2029, a probody drug conjugate (PDC) targeting CD71 and being developed in collaboration with AbbVie, into GLP toxicology studies, an important step on the path to filing an Investigational New Drug (IND) application next year.

Servier, Transgene to apply viral vectorization technology to engineering of allogenic CAR-T

Servier and Transgene have signed a research agreement on the application of viral vectorization technology for the production of allogenic CAR-T cell therapies.

NHS patients in England getting early access to new drugs for lung cancer and sarcoma

NICE's Cancer Drugs Fund (CDF) is driving early access to new drugs for lung cancer and sarcoma for NHS patients in England.

Arix Bioscience buys stake in Mitoconix Bio

Healthcare and life science firm Arix Bioscience has acquired a stake in Mitoconix Bio as part of an oversubscribed $20m Series A financing round.

Cancer frim Repare Therapeutics announces $68m Series A financing

Repare Therapeutics has secured $68m in a Series A financing round which it will use to advance its platform and pipeline of novel medicines that target genetically defined weaknesses of cancers.

Rubius Therapeutics raises $120m to advance red blood cell technology

Rubius Therapeutics, which is developing red-cell therapeutics (RCTs) as a new class of medicines to address a range of indications, has raised $120m in a highly oversubscribed private financing.

eFFECTOR partners with Pfizer, Merck to evaluate combination of two immuno-oncology agents

eFFECTOR Therapeutics has entered into a clinical collaboration and supply agreement with Pfizer and Merck to evaluate the combination of two immuno-oncology agents in patients with microsatellite stable colorectal cancer (CRC).